Fig.5

Relative Sensitivity of QLU-C10D and EQ-5D-3L for Clinically Known Groups (ECOG) across Three Lux-Lung Trials (LL1, LL3, LL8), and Relative Responsiveness of QLU-C10D and EQ-5D-3L to Changes from Baseline to Progression Date in Pooled Data of Lux-Lung 1 and Lux-Lung 8, Using Six Country-Specific Value Sets (Australia, Canada, Italy, the Netherlands, Poland, and the United Kingdom). (A) Horizontal graphs represent range of RE values with six country value set pairs (QLU-C10D & EQ-5D-3L). Icons at each endpoint of the graphs signify country value set pairs with lowest and highest RE value. RE > 1 favors QLU-C10D, RE < 1 favors EQ-5D-3L. Values exceeding the x-axis scale are marked with grey icon “ > ”; (B) Horizontal graphs represent range of differences between effect sizes (LL1, LL3, LL8 = Cohen’s d; pooled data = SRM) calculated with each of the six country value set pairs of the two measures. Icons at the endpoints of the graphs signify country value set pairs with the largest and smallest distances from 0 (= no difference in effect sizes). Differences > 0 favor QLU-C10D, < 0 favor EQ-5D-3L. Abbreviations: ECOG  Eastern Cooperative Oncology Group performance status scale; EOT end of treatment; LL# lux-lung trial number; Pooled All  progressive patients of LL1 & LL8, Pooled Afa.  progressive Patients of LL1 & LL8 treated with Afatinib, RE relative efficiency, SRM  standardized response mean, AUS Australia, CAN  Canada, ITA   Italy, NLD  the Netherlands, POL  Poland,UK  the United Kingdom.